LAS VEGAS, April 27, 2023 /PRNewswire/ -- DelveInsight's
Chronic Kidney Disease Market Insights report includes a comprehensive understanding of current treatment practices, chronic kidney disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]. According to the assessment done by DelveInsight, the estimated total diagnosed prevalent chronic kidney disease cases in the 7MM were approximately ProKidney, Reata Pharmaceuticals, Inc., Novo Nordisk A/S, Boehringer Ingelheim, Eli Lilly and Company, KBP Biosciences, Kibow Pharma, Cincor Pharma, AstraZeneca, Allena Pharmaceuticals, DiaMedica Therapeutics Inc, Lexicon Pharmaceuticals, Sanofi, and others are developing novel chronic kidney disease drugs that can be available in the chronic kidney disease market in the coming years. Renal Autologous Cell Therapy (REACT), Bardoxolone methyl, Ziltivekimab, Semaglutide, JARDIANCE (empagliflozin), KBP-5074, KT-301, CIN-107 (Baxdrostat), Zibotentan, ALLN-346, DM199, Sotagliflozin Chronic kidney disease occurs when the kidneys get damaged and cannot filter blood as efficiently as they should. Chronic kidney disease is defined as abnormalities in kidney structure or function that have been present for more than three months and have a negative impact on health. Chronic kidney disease is categorized into five phases based on the extent of kidney damage and function. In stage 1, there is modest kidney disease, and in stage 5, the kidneys have stopped working. The severity of chronic kidney disease varies. In the early stages of kidney disease, there are usually no chronic kidney disease symptoms. It can only be diagnosed if a blood or urine test is performed for another reason and the results show a kidney issue. Tiredness, swollen ankles, feet, or hands, shortness of breath, unwellness, and blood in the urine indicate a more advanced stage. Chronic kidney disease can be detected using blood and urine tests. The eGFR blood test measures the efficiency with which the kidneys function. Ultrasound, CT scan, X-ray, and MRI imaging examinations are also used for chronic kidney disease diagnosis. DelveInsight estimates that there were approximately
As per our analysis, chronic kidney disease has been identified as a female-dominant disease, with more females suffering than males. In 2022, 52% of cases of CKD were of females, while 48% of cases were of males in the 7MM.
chronic kidney disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: There are various types of drugs in the chronic kidney disease market. Although available medications cannot cure CKD, they can treat problems and halt future kidney damage. DelveInsight's chronic kidney disease market projection focuses on pharmacological therapy (including all presently utilized off-label medications) recommended for chronic kidney disease management and excludes revenue produced by devices and surgical procedures, including dialysis. KERENDIA, INVOKANA, JYNARQUE, and FARXIGA.
Renal Autologous Cell Therapy (REACT): ProKidney
The dynamics of the chronic kidney disease market are expected to change in the coming years. The emerging treatment pipeline is robustly humongous, attributing to novel MoAs. Moreover, the
rising data on chronic kidney disease and its risk factors is expected to add significantly to the patient pool. Furthermore, the current therapy paradigm includes USD 111 million in 2021 and is anticipated to reach
USD 559 million as its peak revenue. Top SGLT2 players have been competing for lucrative approvals in recent years. The chronic kidney disease market may see another approval with undiagnosed, unreported cases, and unawareness about the disease may also impact future chronic kidney disease market growth. On the contrary, there are significant factors that may contribute to the growth in the market, as chronic kidney disease is associated with major complications, including branded pharmacologic treatment with good safety and efficacy data and broader range coverage like impulse control.
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Chronic Kidney Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted chronic kidney disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Chronic Kidney Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic kidney disease companies, including – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key moderate and severe chronic kidney disease companies, including Moderate and Severe Chronic Kidney Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key moderate and severe chronic kidney disease companies, including – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key anemia in chronic kidney disease companies, including Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Connect with us on LinkedIn
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg